MedTrace Logo

PENG vs Femoral Block for Hip Fracture Analgesia

NCT07073209 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 352

Last updated 2026-05-15

No results posted yet for this study

Summary

This study aims to compare the Pericapsular Nerve Group (PENG) block with femoral block for hip fracture pain. Participants presenting to the hospital with a diagnosis of hip fracture and consenting to analgesic block will receive either a PENG or femoral block. The choice of block will be dictated by a randomized monthly schedule, and all participants presenting during each four-week period will receive the designated block. A sub-group analysis will be performed to determine any difference in efficacy in participants with intracapsular versus extracapsular fractures.

Conditions

  • Hip Fractures

Interventions

PROCEDURE

PENG Block Administration

Policy for the PENG block administration: 30 mL of Bupivacaine 0.25% 1:200,000 epinephrine Dexamethasone 4 mg% While these drugs are administered to participants, the intervention under evaluation is the PENG Block anesthesia technique.

PROCEDURE

Femoral Block Administration

Policy for the Femoral block administration: 30 mL of Bupivacaine 0.25% 1:200,000 epinephrine Dexamethasone 4 mg While these drugs are administered to participants, the intervention under evaluation is the Femoral Block anesthesia technique.

DRUG

Bupivacaine , epinephrine Dexamethasone

30 mL of Bupivacaine 0.25% 1:200,000 epinephrine Dexamethasone 4 mg%

Sponsors & Collaborators

  • New York Presbyterian Hospital

    collaborator OTHER

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • Tiffany Tedore, MD · Weill Medical College of Cornell University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-10
Primary Completion
2027-03-31
Completion
2027-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07073209 on ClinicalTrials.gov